[go: up one dir, main page]

DK2301544T3 - Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer - Google Patents

Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer

Info

Publication number
DK2301544T3
DK2301544T3 DK10154018.5T DK10154018T DK2301544T3 DK 2301544 T3 DK2301544 T3 DK 2301544T3 DK 10154018 T DK10154018 T DK 10154018T DK 2301544 T3 DK2301544 T3 DK 2301544T3
Authority
DK
Denmark
Prior art keywords
intermediates
quinoline derivatives
mycobacterial inhibitors
mycobacterial
inhibitors
Prior art date
Application number
DK10154018.5T
Other languages
English (en)
Inventor
Marc Gaston Venet
Daniel Frank Jean Vernier
Imre Christian Francis Csoka
Jerome Emile Georges Guillemont
Laurence Francoise Bernadette Decrane
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31188461&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2301544(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK2301544T3 publication Critical patent/DK2301544T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4
    • C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/36—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
DK10154018.5T 2002-07-25 2003-07-18 Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer DK2301544T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39871102P 2002-07-25 2002-07-25

Publications (1)

Publication Number Publication Date
DK2301544T3 true DK2301544T3 (da) 2013-01-02

Family

ID=31188461

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03771115.7T DK1527050T3 (da) 2002-07-25 2003-07-18 Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer
DK10154018.5T DK2301544T3 (da) 2002-07-25 2003-07-18 Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK03771115.7T DK1527050T3 (da) 2002-07-25 2003-07-18 Quinolin-derivater og deres anvendelse som mycobakterielle inhibitorer

Country Status (38)

Country Link
US (1) US7498343B2 (da)
EP (2) EP1527050B1 (da)
JP (1) JP4484703B2 (da)
KR (1) KR100733577B1 (da)
CN (2) CN1325475C (da)
AP (1) AP2421A (da)
AR (1) AR040673A1 (da)
AT (1) ATE463482T1 (da)
AU (1) AU2003262529B2 (da)
BE (1) BE2014C051I2 (da)
BR (1) BRPI0312927B8 (da)
CA (1) CA2493225C (da)
CY (3) CY1111882T1 (da)
DE (1) DE60332023D1 (da)
DK (2) DK1527050T3 (da)
EA (1) EA008937B1 (da)
ES (2) ES2343458T3 (da)
FR (1) FR14C0060I2 (da)
HK (2) HK1083496A1 (da)
HR (2) HRP20050045B1 (da)
HU (1) HUS1400047I1 (da)
IL (2) IL166457A (da)
IS (1) IS2914B (da)
LU (1) LU92520I2 (da)
ME (1) ME00131B (da)
MX (1) MXPA05001052A (da)
MY (1) MY143564A (da)
NL (1) NL300684I2 (da)
NO (2) NO329935B1 (da)
NZ (1) NZ538391A (da)
PL (1) PL222801B1 (da)
PT (2) PT2301544E (da)
RS (1) RS52431B (da)
SI (2) SI1527050T1 (da)
TW (1) TWI323730B (da)
UA (1) UA82198C2 (da)
WO (1) WO2004011436A1 (da)
ZA (1) ZA200500680B (da)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7338949B2 (en) * 2004-01-23 2008-03-04 Janssen Pharmaceutica N.V. Mycobacterial inhibitors
UA86952C2 (uk) * 2004-01-23 2009-06-10 Янссен Фармацевтика Н.В. Похідні хіноліну та їх застосування як мікобактеріальних інгібіторів
EA011572B9 (ru) * 2004-01-29 2018-01-31 Янссен Фармацевтика Н.В. Производные хинолина для применения в качестве микобактериальных ингибиторов
DK1753427T3 (da) * 2004-05-28 2008-07-21 Janssen Pharmaceutica Nv Anvendelse af substituerede quinolinderivater til behandling af lægemiddelresistente mykobakteriesygdomme
US8088891B2 (en) * 2004-09-28 2012-01-03 Janssen Pharmaceutica N.V. Bacterial ATP synthase binding domain
KR101301573B1 (ko) * 2004-12-24 2013-09-04 얀센 파마슈티카 엔.브이. 잠재성 튜버큐로시스의 치료법
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
PL1888604T3 (pl) * 2005-05-25 2012-08-31 Janssen Pharmaceutica Nv Sposób wytwarzania (alfa S, beta R)-6-bromo-alfa-[2-(dimetyloamino)etylo]-2-metoksy-alfa-1-naftalenylo-beta-fenylo-3-chinolinetanolu
TWI380819B (zh) * 2005-06-08 2013-01-01 Janssen Pharmaceutica Nv 用作抗細菌劑之喹啉衍生物
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents
JP5349730B2 (ja) * 2005-06-09 2013-11-20 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 抗バクテリア剤としてのキノリン誘導体
KR101318181B1 (ko) * 2005-06-09 2013-10-16 얀센 파마슈티카 엔.브이. 항균제로서의 퀴놀린 유도체
EA010601B1 (ru) * 2005-06-09 2008-10-30 Янссен Фармацевтика Н.В. Производные хинолина в качестве антибактериальных агентов
JO2752B1 (en) * 2005-06-28 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
CN101252927B (zh) * 2005-06-28 2014-01-01 詹森药业有限公司 作为抗菌剂的喹啉衍生物
JO3270B1 (ar) * 2005-06-28 2018-09-16 Janssen Pharmaceutica Nv مشتقات كوينولين بصفة عوامل مضادة للبكتيريا
JO3077B1 (ar) * 2005-07-28 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينولين مضادة للبكتيريا
JO2855B1 (en) * 2005-08-03 2015-03-15 شركة جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2952B1 (en) * 2005-08-03 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline derivatives acting as antibacterial agents
JO2837B1 (en) 2005-08-03 2014-09-15 جانسن فارمسيتكا ان في Quinoline derivatives acting as antibacterial agents
EP1917245A1 (de) 2005-08-21 2008-05-07 Abbott GmbH & Co. KG Heterocyclische verbindungen und ihre verwendung als bindungspartner für 5-ht5-rezeptoren
DE102005044817A1 (de) 2005-09-20 2007-03-22 Sanofi-Aventis Deutschland Gmbh Substituierte 4-Phenyltetrahydroisochinoline, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament, sowie sie enthaltendes Medikament
UA97813C2 (uk) * 2006-12-05 2012-03-26 Янссен Фармацевтика Н.В. Фумаратна сіль (альфа s, бета r)-6-бром-альфа-[2-(диметиламіно)етил]-2-метоксі-альфа-1-нафталеніл-бета-феніл-3-хінолінетанолу
JO2685B1 (en) 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2684B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان في Quinoline antibacterial derivatives
JO2725B1 (en) * 2006-12-06 2013-09-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO2683B1 (en) * 2006-12-06 2013-03-03 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
JO3271B1 (ar) * 2006-12-06 2018-09-16 Janssen Pharmaceutica Nv مشتقات الكوينولين المضادة للجراثيم
JO2970B1 (en) * 2006-12-06 2016-03-15 جانسين فارماسوتيكا ان. في Quinoline antibacterial derivatives
RU2404971C2 (ru) * 2008-12-02 2010-11-27 ЗАО "Фарм-Синтез" Новые производные хинолина, способ их получения, их применение для лечения микобактериальных инфекций, фармацевтическая композиция на их основе
CN102249935B (zh) * 2010-05-17 2015-05-20 中国人民解放军军事医学科学院毒物药物研究所 芳香2-丁醇类化合物及其医药用途
RU2486175C2 (ru) * 2011-09-12 2013-06-27 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 5,6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ получения и применение соединений
PL2841426T3 (pl) 2012-04-27 2017-03-31 Janssen Pharmaceutica N.V. Przeciwbakteryjne pochodne chinoliny
CN104254527B (zh) 2012-04-27 2017-05-31 詹森药业有限公司 抗菌的喹啉衍生物
WO2014014845A1 (en) 2012-07-18 2014-01-23 Vertex Pharmaceuticals Incorporated Combination therapy comprising|1 -ethyl-3-[5-[2-{1 -hydroxy-1 -methyl-ethyl}pyrimidin-5-yl]-7-(tetra hydrofuran-2-|yl}-1 h-benzimidazol-2-yl]urea and derivatives thereof to treat mycobacterium|diseases
KR102233199B1 (ko) 2012-12-21 2021-03-30 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균성 화합물
RU2530493C1 (ru) * 2013-04-22 2014-10-10 Закрытое Акционерное Общество "Фарм-Синтез" Производные хинолина, в частности 6,7-замещенные 1-(2-хлорхинолин-3-ил)-4-диметиламино-2-(нафталин-1-ил)-1-фенилбутан-2-олы, способ их получения и применение соединений для лечения инфекционных заболеваний микобактериальной природы, в частности туберкулеза
CN105017147B (zh) * 2014-04-30 2019-02-01 中国医学科学院药物研究所 一种回收和利用Bedaquiline立体化学异构体的方法
CN105085395B (zh) * 2014-05-07 2017-09-26 国药集团国瑞药业有限公司 贝达喹啉的制备方法
CN105085396B (zh) * 2014-05-07 2017-08-08 国药集团国瑞药业有限公司 用于制备贝达喹啉的中间体及其制备方法和应用
CN105198808B (zh) * 2014-05-27 2017-08-25 北京万生药业有限责任公司 一种高效生产贝达喹啉的方法
CN105175329B (zh) * 2014-06-10 2017-09-19 重庆圣华曦药业股份有限公司 一种贝达喹啉消旋体的合成路线及方法
WO2016008381A1 (zh) * 2014-07-14 2016-01-21 辰欣药业股份有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105330595B (zh) * 2014-07-14 2019-12-10 上海嘉坦医药科技有限公司 吡啶衍生物及其作为抗分支杆菌的应用
CN105440051B (zh) * 2014-09-19 2019-07-05 重庆医药工业研究院有限责任公司 一种抗结核的噻吩吡啶衍生物
CZ2014708A3 (cs) 2014-10-16 2016-04-27 Zentiva, K.S. Soli Bedaquilinu
CZ201535A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201534A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Nové možnosti chirální resoluce bedaquilinu
CZ201533A3 (cs) 2015-01-21 2016-08-03 Zentiva, K.S. Způsob izolace směsi enantiomerů
KR102631986B1 (ko) 2015-01-27 2024-01-30 얀센 파마슈티카 엔브이 분산성 조성물
WO2016174673A1 (en) * 2015-04-29 2016-11-03 The State Of Israel, Ministry Of Agriculture & Rural Development, Agricultural Research Organization (Aro) (Volcani Center) Anti-phytopathogenic compositions
CN106279017A (zh) * 2015-05-21 2017-01-04 重庆圣华曦药业股份有限公司 贝达喹啉晶型、组合物及其制备方法
CZ2015391A3 (cs) 2015-06-09 2016-12-21 Zentiva, K.S. Sůl bedaquilinu s kyselinou citronovou
CA2986331A1 (en) 2015-07-02 2017-01-05 Janssen Sciences Ireland Uc Antibacterial compounds
CN105061387A (zh) * 2015-07-17 2015-11-18 苏州大学 二芳基醚类稠环类化合物、制备方法和用途
CN107848978B (zh) * 2015-07-24 2021-04-02 浙江海正药业股份有限公司 一种分离贝达喹啉非对映异构体a的方法
EP3366676B1 (en) 2015-10-20 2021-05-26 Zhejiang Hisun Pharmaceutical Co., Ltd Crystalline forms of bedaquiline fumarate and preparation methods therefor
WO2017121323A1 (zh) * 2016-01-13 2017-07-20 辰欣药业股份有限公司 一种吡啶衍生物类化合物的制备方法及其中间体和晶型
WO2017149551A1 (en) * 2016-03-03 2017-09-08 Council Of Scientific & Industrial Research Substituted aurone alkaloids as anti-mycobacterial agents
US10508097B2 (en) * 2016-03-07 2019-12-17 The Global Alliance For Tb Drug Development, Inc. Antibacterial compounds and uses thereof
AU2017286368B2 (en) 2016-06-16 2021-02-25 Janssen Sciences Ireland Unlimited Company Heterocyclic compounds as antibacterials
KR20190018681A (ko) 2016-06-16 2019-02-25 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 항균제로서의 헤테로고리 화합물
BR112019017901A2 (pt) 2017-03-01 2020-05-12 Janssen Sciences Ireland Unlimited Company Terapia de combinação
RS62362B1 (sr) 2017-07-14 2021-10-29 Janssen Pharmaceutica Nv Formulacije sa dugotrajnim dejstvom
CN109384716B (zh) * 2017-08-11 2021-06-29 海创药业股份有限公司 一种氘代喹啉化合物及其制备和用途
EP3908269A1 (en) 2019-01-09 2021-11-17 Janssen Pharmaceutica NV Combination in the treatment of nontuberculous mycobacterial diseases
WO2020161743A1 (en) 2019-02-08 2020-08-13 Mylan Laboratories Limited Process for the preparation of bedaquiline fumarate
US20220340564A1 (en) 2019-09-13 2022-10-27 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2021057190A1 (zh) * 2019-09-29 2021-04-01 上海阳帆医药科技有限公司 喹啉类化合物、其制备方法和用途
AU2020360560A1 (en) 2019-09-30 2022-03-10 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
AU2020358643A1 (en) 2019-09-30 2022-05-26 Janssen Sciences Ireland Unlimited Company 4-quinolinone antibacterial compounds
CN110804016B (zh) * 2019-12-05 2022-11-04 福建省微生物研究所 抗结核分枝杆菌的二芳基喹啉衍生物
BR112022012704A2 (pt) 2019-12-27 2022-09-06 Tecnimede Sociedade Tecnico Medicinal Sa Quinolinas antibacterianas.
KR102303635B1 (ko) 2020-07-01 2021-09-17 동아에스티 주식회사 (1r,2s)-1-(6-브로모-2-메톡시퀴놀린-3-일)-4-디메틸아미노-2-(1-나프틸)-1-페닐-부탄-2-올 및 이의 약제학적으로 허용 가능한 염의 제조방법
BR112023000220A2 (pt) 2020-07-09 2023-01-31 Janssen Pharmaceutica Nv Formulações de longa ação
CA3184868A1 (en) 2020-07-09 2022-01-13 Rene Holm Long-acting formulations
CN115776882A (zh) 2020-07-09 2023-03-10 詹森药业有限公司 长效配制品
WO2022101244A1 (en) 2020-11-12 2022-05-19 Janssen Pharmaceutica Nv Combination of bedaquiline, ethambutol and a macrolide in the treatment of nontuberculous mycobacterial diseases
US20240199611A1 (en) 2021-03-16 2024-06-20 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022194906A1 (en) 2021-03-17 2022-09-22 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
US20240199651A1 (en) 2021-03-17 2024-06-20 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214519A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2022214520A1 (en) 2021-04-07 2022-10-13 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2023275744A1 (en) 2021-06-29 2023-01-05 TECNIMEDE - Sociedade Técnico-medicinal, SA Heterocyclic compounds for the treatment of tuberculosis
TW202325274A (zh) 2021-10-28 2023-07-01 愛爾蘭商健生科學愛爾蘭無限公司 抗菌化合物
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CN114835641B (zh) * 2022-05-07 2024-03-15 南京杰运医药科技有限公司 一种3-苄基-6-溴-2-甲氧基喹啉的合成方法
WO2023217279A1 (zh) * 2022-05-13 2023-11-16 广州嘉越医药科技有限公司 一种吡啶衍生物、中间体、制备方法和应用
WO2023232838A1 (en) 2022-05-31 2023-12-07 Janssen Pharmaceutica Nv Bedaquiline for use in the treatment of leprosy
WO2024068693A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024068699A1 (en) 2022-09-28 2024-04-04 Janssen Pharmaceutica Nv Long-acting formulations
WO2024089170A1 (en) 2022-10-27 2024-05-02 Janssen Sciences Ireland Unlimited Company Antibacterial compounds
WO2024107555A1 (en) 2022-11-15 2024-05-23 Eli Lilly And Company Ahr agonists
WO2024223859A1 (en) 2023-04-26 2024-10-31 Janssen Pharmaceutica Nv Antibacterial compounds

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0936866A4 (en) * 1996-10-28 2001-04-11 Dept Of The Army Us Government Compounds, compositions and methods for treating antibiotic-resistant infections
US6103905A (en) * 1997-06-19 2000-08-15 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AU757059B2 (en) * 1997-06-19 2003-01-30 Sepracor, Inc. Quinoline-indole antimicrobial agents, uses and compositions related thereto
AU6645198A (en) * 1998-01-23 1999-08-09 Fire Armour Pte Ltd Nozzle with axially and perpendicularly directed apertures
JP2002501061A (ja) * 1998-01-26 2002-01-15 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 抗菌剤用キノリン誘導体
US6819431B2 (en) * 2001-07-06 2004-11-16 Zygo Corporation Polymer retarder
EE05394B1 (et) * 2004-12-24 2011-04-15 Janssen Pharmaceutica N.V. Kinoliinihendid kasutamiseks latentse tuberkuloosi ravis
CA2528849C (en) * 2005-06-08 2014-01-14 Janssen Pharmaceutica N.V. Quinoline derivatives as antibacterial agents

Also Published As

Publication number Publication date
EP2301544A1 (en) 2011-03-30
HRP20050045A2 (en) 2006-06-30
HRP20120190A2 (hr) 2012-05-31
KR100733577B1 (ko) 2007-06-29
CN101070304B (zh) 2011-10-26
HRP20050045B1 (hr) 2013-09-30
CY2014033I2 (el) 2016-04-13
PT2301544E (pt) 2012-12-10
NO329935B1 (no) 2011-01-24
EP1527050B1 (en) 2010-04-07
JP2006504658A (ja) 2006-02-09
CN1325475C (zh) 2007-07-11
ZA200500680B (en) 2006-08-30
NZ538391A (en) 2005-10-28
EA200500257A1 (ru) 2005-06-30
IL166457A (en) 2011-10-31
TW200410939A (en) 2004-07-01
MY143564A (en) 2011-05-31
ME00131B (me) 2010-10-10
US20050148581A1 (en) 2005-07-07
HRP20120190B1 (hr) 2017-06-02
LU92520I2 (fr) 2015-11-02
CN101070304A (zh) 2007-11-14
CY1113497T1 (el) 2016-06-22
IL166457A0 (en) 2006-01-15
UA82198C2 (uk) 2008-03-25
AR040673A1 (es) 2005-04-13
HUS1400047I1 (hu) 2016-09-28
PT1527050E (pt) 2010-06-22
FR14C0060I2 (fr) 2015-11-20
AU2003262529B2 (en) 2009-11-19
BE2014C051I2 (da) 2022-08-09
US7498343B2 (en) 2009-03-03
BRPI0312927B8 (pt) 2021-05-25
RS20050058A (en) 2007-06-04
WO2004011436A1 (en) 2004-02-05
HK1113795A1 (en) 2008-10-17
AP2421A (en) 2012-06-08
PL375523A1 (en) 2005-11-28
BRPI0312927B1 (pt) 2018-07-10
CY2014033I1 (el) 2016-04-13
NO2014021I1 (no) 2014-08-20
HRP20120190A8 (en) 2012-07-31
ES2343458T3 (es) 2010-08-02
AU2003262529A1 (en) 2004-02-16
CY1111882T1 (el) 2015-11-04
CA2493225C (en) 2012-03-20
MEP9208A (en) 2010-06-10
EA008937B1 (ru) 2007-10-26
IS2914B (is) 2014-12-15
EP1527050A1 (en) 2005-05-04
NL300684I2 (da) 2016-10-11
MXPA05001052A (es) 2005-04-08
DK1527050T3 (da) 2010-07-19
SI2301544T1 (sl) 2013-01-31
PL222801B1 (pl) 2016-09-30
IS7620A (is) 2004-12-29
SI1527050T1 (sl) 2010-08-31
CN1671667A (zh) 2005-09-21
ATE463482T1 (de) 2010-04-15
RS52431B (en) 2013-02-28
KR20050033607A (ko) 2005-04-12
AP2005003210A0 (en) 2005-03-31
DE60332023D1 (de) 2010-05-20
IL202655A (en) 2012-04-30
CA2493225A1 (en) 2004-02-05
HK1083496A1 (en) 2006-07-07
NO2014021I2 (da) 2014-08-20
ES2395237T3 (es) 2013-02-11
BR0312927A (pt) 2005-07-12
TWI323730B (en) 2010-04-21
EP2301544B1 (en) 2012-09-19
NO20050476L (no) 2005-01-27
FR14C0060I1 (da) 2014-10-10
JP4484703B2 (ja) 2010-06-16

Similar Documents

Publication Publication Date Title
DK2301544T3 (da) Quinolinderivater som mellemprodukter til mykobakterielle inhibitorer
DK1944305T3 (da) Quinolinderivater som phosphodiesteraseinhibitorer
DK1492785T3 (da) 2-hydroxy-3-heteroarylindol-derivater som GSK3-inhibitorer
NO20043793L (no) Nikotinamidderivater anvendelige som PDE4 inhibitorer
DK1848430T3 (da) Nye benzylamin-derivativer som cetp-inhibitors
NO20055680D0 (no) Heksahydropyridoisokinoliner som DPP-IV-inhibitorer
DK1789041T3 (da) Aryl-pyridinderivater som 11-beta-HSD1-inhibitorer
DK1585749T3 (da) Diazepinoindol-derivater som kinaseinhibitorer
DK1492771T3 (da) Quinolin- og isoquinolinderivater, en fremgangsmåde til fremstilling heraf og anvendelse heraf som betændelseshæmmere
DK1797042T3 (da) Indozolonderivater som 11B-HSD1-inhibitorer
DK2130537T3 (da) N3-alkylerede benzimidazolderivater som MEK-inhibitorer
DK2039685T3 (da) Heterobicycliske forbindelser som P38-inhibitorer
NO20043642L (no) Heterocykiske tripeptider som hepatitt C inhibitorer
NO20052887D0 (no) Pyridazinonderivater som GSK-3Beta inhibitorer.
HK1099297A1 (en) Quinoline derivatives for use as mycobacterial inhibitors
DK1436271T6 (da) Phenylpiperazinderivater som serotonin-genoptagelseshæmmere
IS8439A (is) Nýjar kínólín afleiður
AU2003260345A1 (en) 2-phenylpyridin-4-yl derivatives as alk5 inhibitors
NO20044654L (no) Piperidinoylpiperidiner som 5-HTIF-agonister
NO20052818L (no) 2-pyridonderivativer som inhibitorer for neutrofil elastase
NO20050665L (no) Pyrrolidonderivater som MAOE inhibitoere
NO20054880D0 (no) Azaspiroalkanderivater som inhibitorer av metallproeaser
ATE529428T1 (de) Thioxanthinderivate als myeloperoxidaseinhibitoren
DK1633712T3 (da) Seks leddede amino-amid derivater som angiogenese inhibitorer
DE602004018837D1 (de) Ptidase-iv-inhibitoren